Atara Biotherapeutics, Inc.
NASDAQ:ATRABiotechnology
+$0.19 today
- Market cap
- $68.98M
- Beta
- 0.11
- P/E (TTM)
- -14.7
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 1.40M
ATRA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Atara Biotherapeutics, Inc.NASDAQ: ATRA
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$4.14M, compared with $38.01M a year earlier. Trailing-twelve-month net income was -$9.47M.
Context
- Net income amounted to 27.1% of revenue in FY2025, down 39.2 pp from a year earlier.
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$12.99M (-139.7%) for the fiscal year ending Dec 2026, a slowdown from the +138.3% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$4.14M+21.7% QoQ
- Last fiscal yearDec 2025
- $32.69M+138.3% YoY
- LTMMar 2026
- -$9.47M-39.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -110.9% | -302.2% | -191.3 pp |
| 1 year | +138.3% | -139.7% | -278.0 pp |
| 3-year CAGR | — | -39.5% | — |
| 5-year CAGR | +1.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 32.69M USD
- Year-over-year change
- +138.3%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 32.69M | +138.3% |
| FY2024 | 2024-12-31 | (85.4M) | +69.1% |
| FY2023 | 2023-12-31 | (276.13M) | -20.9% |
| FY2022 | 2022-12-31 | (228.3M) | +32.9% |
| FY2021 | 2021-12-31 | (340.14M) | — |
Net Income vs competitors
How ATRA compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -39.5% is the 10th highest of 11, against a peer median of +6.0%.
- Net income amounts to 40.9% of revenue for ATRA, versus a peer median of 302.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $153.6M USD | -37.4% | +17.0% | 154.2% | |
| LTM Mar 2026 | $110M USD | +489.6% | — | — | |
| LTM Mar 2026 | $70.36M USD | +26.1% | -14.6% | 44.8% | |
| LTM Mar 2026 | $49.87M USD | -29.4% | -21.8% | 4987.4% | |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | $40.23M USD | +45.6% | +34.5% | — | |
| LTM Mar 2026 | $33.51M USD | +15.3% | -4.4% | 25009.7% | |
| LTM Mar 2026 | $24.17M USD | -3.2% | -31.5% | 339.3% | |
| LTM Mar 2026 | $21.13M USD | +23.3% | +20.1% | 266.1% | |
| LTM Mar 2026 | $9.47M USD | -39.5% | — | 40.9% | |
| LTM Jan 2026 | $2.34M USD | -136.5% | +104.7% | 4.0% | |
| Peer median (excluding ATRA) | — | +6.0% | +14.1% | 302.7% | |
Competitors are the stored peer set for ATRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (340.14M) | (228.3M) | (276.13M) | (85.4M) | 32.69M |
| Depreciation & Amortization | 9.35M | 5.65M | 4.83M | 5.05M | 2.38M |
| Deferred Income Tax | 1.79M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 53.87M | 53.84M | 45.39M | 27M | 9.75M |
| Change in Working Capital | 52.58M | (61.47M) | 15.34M | (30.96M) | (104.74M) |
| Accounts Receivables | 264K | (39.24M) | 6.11M | 32.63M | 229K |
| Inventory | 3.34M | (1.59M) | (8.12M) | (4.43M) | 10.66M |
| Accounts Payables | 9.07M | (9.21M) | (3.13M) | 687K | (4.24M) |
| Other Working Capital | 39.91M | (11.44M) | 20.48M | (59.84M) | (111.38M) |
| Other Non-Cash Items | 2.04M | (40.15M) | 17.59M | 15.59M | 8.98M |
| Operating Cash Flow | (220.52M) | (270.43M) | (192.98M) | (68.72M) | (50.94M) |
| Capital Expenditures | (10.58M) | (4.19M) | (1.22M) | (246K) | 0 |
| Acquisitions (Net) | (32.84M) | 0 | 0 | 0 | 948K |
| Purchases of Investments | (301.13M) | (180.59M) | (83.65M) | (19.67M) | (7.89M) |
| Sales of Investments | 333.97M | 292.97M | 208.71M | 28.54M | 25.09M |
| Other Investing Activities | 32.84M | 94.77M | 25K | 0 | 0 |
| Investing Cash Flow | 22.26M | 202.96M | 123.87M | 8.62M | 18.15M |
| Debt Repayment | (254K) | (518K) | (947K) | (892K) | (250K) |
| Common Stock Issued | 98.7M | 21.89M | 2.14M | 59.95M | 16.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 5.5M | 31.71M | 821K | 223K | (1K) |
| Financing Cash Flow | 103.94M | 53.08M | 2.01M | 59.28M | 16.1M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (94.32M) | (14.39M) | (67.1M) | (811K) | (16.69M) |
| Free Cash Flow | (231.1M) | (274.62M) | (194.2M) | (68.96M) | (50.94M) |
Atara Biotherapeutics, Inc.
NASDAQ:ATRA
Intrinsic Alpha fair value
Locked
Current Price
$6.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.